A Registry Study in Lymphoma Patients Treated With Liposomal Doxorubicin
NCT04069845 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 2000
Last updated 2021-03-17
Summary
This study is to evaluate the incidence of interstitial pneumonia in lymphoma patients treated with liposomal doxorubucin. The treatment response and other adverse events will also be studied.
Conditions
Interventions
- DRUG
-
liposomal doxorubicin
intravenous liposomal doxorubicin
Sponsors & Collaborators
-
Ruijin Hospital
lead OTHER
Eligibility
- Min Age
- 18 Years
- Max Age
- 80 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2019-08-01
- Primary Completion
- 2021-08-01
- Completion
- 2021-08-30
Countries
- China
Study Locations
More Related Trials
-
Study of Ulevostinag (MK-1454) Alone or in Combination With Pembrolizumab (MK-3475) in Participants With Advanced/Metastatic Solid Tumors or Lymphomas (MK-1454-001)
NCT03010176 ·Status: COMPLETED ·Phase: PHASE1
-
A Clinical Trial of B019 Injection in Patients With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma.
NCT06970496 ·Status: NOT_YET_RECRUITING ·Phase: PHASE1
-
Feasibility Study Of Adding Bortezomib to R-ICE Chemotherapy To Treat Relapsed/ Refractory Diffuse Large B-Cell Lymphoma
NCT01226849 ·Status: COMPLETED ·Phase: PHASE1
-
Lenalidomide Combined With R-CHOP(R2-CHOP) in Newly Diagnosed Double-expressor Diffuse Large B-Cell Lymphoma Patients
NCT04164368 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of LY2835219 in Japanese Participants With Advanced Cancer
NCT02014129 ·Status: COMPLETED ·Phase: PHASE1
-
Study of Copanlisib in Combination With Standard Immunochemotherapy in Relapsed Indolent Non-Hodgkin's Lymphoma (iNHL)
NCT02626455 ·Status: TERMINATED ·Phase: PHASE3
-
Safety Study of Rituximab (SC) Administered in Participants With CD20+ DLBCL or CD20+ Follicular NHL Grade 1 to 3A
NCT02406092 ·Status: COMPLETED ·Phase: PHASE3
-
Mitoxantrone Hydrochloride Liposome Injection in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
NCT05875428 ·Status: UNKNOWN ·Phase: PHASE2
-
Safety and Early Signs of Efficacy of IL12-L19L19.
NCT04471987 ·Status: RECRUITING ·Phase: PHASE1
-
Study of TJ011133 in Participants With Relapsed/Refractory Advanced Solid Tumors and Lymphoma
NCT03934814 ·Status: COMPLETED ·Phase: PHASE1
-
Pegylated Liposomal Doxorubicin Containing Chemotherapy in the Treatment of Older Non-Hodgkin's Lymphoma Patients
NCT00120198 ·Status: TERMINATED ·Phase: PHASE2
-
A Study of Two Associations of Rituximab and Chemotherapy, With a PET-driven Strategy, in Lymphoma
NCT00498043 ·Status: COMPLETED ·Phase: PHASE2
-
The Study of Pegylated Liposomal Doxorubicin Contrast Epirubicin for the Treatment of Diffuse Large B-cell Lymphoma
NCT03022123 ·Status: UNKNOWN ·Phase: NA
-
Pegylated Liposomal Doxorubicin (Doxil) With Rituximab in Relapsed AIDS-Related Non-Hodgkin's Lymphomas
NCT00183976 ·Status: TERMINATED ·Phase: PHASE2
-
Toripalimab Combine With Rituximab for Treatment of Relapsed Refractory CD20 Positive Diffuse Large B-cell Lymphoma
NCT04425824 ·Status: UNKNOWN ·Phase: PHASE2
-
A Study to Evaluate the Efficacy and Safety of ICP-248 in Subjects With Relapsed or Refractory Mantle Cell Lymphoma (APEX-06)
NCT07082686 ·Status: RECRUITING ·Phase: PHASE2
-
LBH589 in Adult Patients With Advanced Solid Tumors or Cutaneous T-cell Lymphoma
NCT00412997 ·Status: COMPLETED ·Phase: PHASE1
-
Biomarker Guided Treatment in DLBCL
NCT04025593 ·Status: UNKNOWN ·Phase: PHASE2
-
A Study of LY2584702 in Solid Tumors
NCT01241461 ·Status: COMPLETED ·Phase: PHASE1
-
A Study of Rocbrutinib in Participants With Relapse or Refractory Non-GCB Diffuse Large B-Cell Lymphoma
NCT07189065 ·Status: RECRUITING ·Phase: PHASE2
-
A Single-cell Transcriptome Study in Patients With Non-Hodgkin's Lymphoma
NCT04434833 ·Status: UNKNOWN
-
Study of LP002 for the Treatment of Patients With Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma
NCT04600947 ·Status: UNKNOWN ·Phase: PHASE2
-
RGL-305+ Lymphoma + Exploratory Clinical Study
NCT07006012 ·Status: RECRUITING ·Phase: NA
-
Phase Ⅰ/Ⅱ Study of SHR2554 in Combination With SHR1701 in Patients With Advanced Solid Tumors and B-cell Lymphomas
NCT04407741 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
R Retreatment in 1st Relapsed DLBCL
NCT00980304 ·Status: UNKNOWN ·Phase: PHASE2